Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Event Profile and Management of ILD and Ocular Surface Events with Datroway in Japan
jRCT2031260195Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of darunavir + cobicistat in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Interstitial lung disease (ILD) events and Ocular surface events (OSE). Planned start Apr 2027; status: active, not recruiting.
02
Drugs
darunavir + cobicistat
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031260195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260195.